Market momentum builds: Social media chatter around Tempus AI has centered on the stock's recent attempts to break through key resistance levels amid broader AI healthcare trends. Analysts and traders note the company's push toward profitability by year-end as a key driver of interest. Discussions highlight partnerships with major pharma firms as potential catalysts.
Short-term trading focus: Recent posts emphasize chart patterns and wave analysis suggesting possible upside moves toward higher targets if current levels hold. Participants point to strong revenue growth and data platform advantages without assigning specific valuations. Some caution remains over dilution from recent share offerings.
Sector tailwinds noted: Broader conversations link $TEM to improving conditions in biotech and diagnostics, with emphasis on its AI integration in oncology and cardiology. Traders express interest in monitoring institutional flows and earnings updates. Overall tone reflects steady engagement with the name.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI Insider Trading Activity
Tempus AI insiders have traded $TEM stock on the open market 52 times in the past 6 months. Of those trades, 0 have been purchases and 52 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
- ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 36 sales selling 1,033,422 shares for an estimated $57,086,991.
- ANDREW POLOVIN (EVP, Chief Legal Officer) has made 0 purchases and 4 sales selling 27,795 shares for an estimated $1,524,677.
- RYAN FUKUSHIMA (CEO, Data) has made 0 purchases and 3 sales selling 28,142 shares for an estimated $1,484,856.
- JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 2 sales selling 20,937 shares for an estimated $1,073,751.
- ERIK PHELPS (EVP, Chief Admin. Officer) has made 0 purchases and 2 sales selling 9,464 shares for an estimated $562,472.
- RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 7,018 shares for an estimated $352,755.
- THOMAS EDWARD SCHOENHERR (CEO, Diagnostics) sold 1,580 shares for an estimated $69,630
- DAVID R EPSTEIN has made 0 purchases and 2 sales selling 620 shares for an estimated $34,331.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Tempus AI Revenue
Tempus AI had revenues of $348.1M in Q1 2026. This is an increase of 36.12% from the same period in the prior year.
You can track TEM financials on Quiver Quantitative's TEM stock page.
You can access data on TEM stock through the Quiver Quantitative API.
Tempus AI Congressional Stock Trading
Members of Congress have traded $TEM stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TEM stock by members of Congress over the last 6 months:
- REPRESENTATIVE NANCY PELOSI purchased up to $100,000 on 01/16.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Tempus AI Hedge Fund Activity
We have seen 254 institutional investors add shares of Tempus AI stock to their portfolio, and 262 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 1,750,525 shares (+118.0%) to their portfolio in Q1 2026, for an estimated $79,158,740
- BLACKROCK, INC. added 1,452,220 shares (+19.3%) to their portfolio in Q1 2026, for an estimated $65,669,388
- BAILLIE GIFFORD & CO removed 950,999 shares (-9.8%) from their portfolio in Q4 2025, for an estimated $56,156,490
- D. E. SHAW & CO., INC. removed 847,169 shares (-41.8%) from their portfolio in Q4 2025, for an estimated $50,025,329
- AMOVA ASSET MANAGEMENT AMERICAS, INC. added 821,490 shares (+23.4%) to their portfolio in Q1 2026, for an estimated $37,147,777
- SUMITOMO MITSUI TRUST GROUP, INC. added 821,490 shares (+23.4%) to their portfolio in Q1 2026, for an estimated $37,147,777
- VANGUARD GROUP INC added 817,014 shares (+8.7%) to their portfolio in Q4 2025, for an estimated $48,244,676
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Tempus AI Government Contracts
We have seen $20,963,166 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ADAPT CRO SUPPORT SERVICES SOLICITATION: $12,741,975
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Tempus AI Analyst Ratings
Wall Street analysts have issued reports on $TEM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 12/22/2025
To track analyst ratings and price targets for Tempus AI, check out Quiver Quantitative's $TEM forecast page.
Tempus AI Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 11 analysts offer price targets for $TEM in the last 6 months, with a median target of $68.0.
Here are some recent targets:
- Ryan MacDonald from Needham set a target price of $75.0 on 06/01/2026
- Mark Massaro from BTIG set a target price of $80.0 on 06/01/2026
- Yi Chen from HC Wainwright & Co. set a target price of $64.0 on 05/11/2026
- Dan Brennan from TD Cowen set a target price of $68.0 on 05/06/2026
- Tycho Peterson from Jefferies set a target price of $35.0 on 04/13/2026
- Subbu Nambi from Guggenheim set a target price of $60.0 on 03/30/2026
- Tejas Savant from Morgan Stanley set a target price of $70.0 on 03/03/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
